JPRN-UMIN000053317招募中Unknown
A phase II study to evaluate the safety of first-time radical gastrectomy by robotic approach for stomach cancer in an early stage - ERSTE-M study
Iwate Prefectural Isawa Hospital0 个研究点目标入组 22 人开始时间: 2024年1月10日最近更新:
适应症
试验速览
- 阶段
- Unknown
- 状态
- 招募中
- 发起方
- 入组人数
- 22
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional
入排标准
- 年龄范围
- 20years-old 至 ot applicable（—）
- 性别
- All
入选标准
- 未提供
排除标准
- •1)Synchronous or metachronous (within 5 years) malignancies. 2)During pregnancy, within 28 days postpartum, or during lactation. 3)Severe mental disease. 4)Receiving continuous systemic corticosteroid or immunosuppressant treatment. 5)History of unstable angina pectoris within three weeks or myocardial infarction within six months before registration. 6)Poorly controlled hypertension. 7)Uncontrolled diabetes mellitus. 8)Respiratory disease requiring continuous oxygen administration.
研究者
相似试验
尚未招募
不适用
A 2-step phase I study evaluating the safety of (neo-)adjuvant cisplatin-pemetrexed and stereotactic radiotherapy for patients with stage IB non-small-cell lung cancerlung carcinoma10038666lung cancerNL-OMON32798Vrije Universiteit Medisch Centrum20
终止
2 期
A 2-stage Phase II study of combination pomalidomide and low dose dexamethasone therapy in patients with relapsed myeloma previously treated wtih lenalidomide maintenance post Autologous Stem Cell Transplant (LEOPARD follow-on study)ACTRN12615000447550Alfred Health30
进行中（未招募）
1 期
A Study of MK-1088 as monotherapy and in combination with pembrolizumab in patients with advanced solid tumorsCTIS2022-502288-40-00Merck Sharp & Dohme LLC95
进行中（未招募）
1 期
A Phase 1/Phase 2 Study to Evaluate the Safety and Tolerability of MK-1088 as Monotherapy/ single agent and in Combination with Pembrolizumab in Participants with Advanced Solid TumorsEUCTR2021-006712-93-DKMerck Sharp & Dohme LLC80
进行中（未招募）
1 期
aEUCTR2019-004883-23-FRAPHP